Frank Baas
Senior Vice President, Research Graviton BioSciences
Frank Baas (25 februari, 1956) is Professor of Molecular Genetic Diagnostics and head of the laboratory for genome diagnostics (LDGA) of the Department of Clinical Genetics. He is also visting scientist at the Koch Institute of the Massachusetts Institute of Technology and co-founder of Regenesance and Complement Pharma BV. He is member of the scientic advisory boards of Stichting MS Research, the American Charcot-Marie-Tooth organisation and ad hoc member of review committies of the Belgian FWO and the Portugese FCT.
Seminars
NEW SPEAKING COMPANY
Whilst complement dysregulation is observed across a broad range of diseases, it remains unclear where complement therapeutics can deliver maximum benefit to patients whilst maintaining healthy immune function.
This workshop will cover:
- Evaluating which indications offer the greatest opportunity for complement intervention and determining where complement biology is most likely to translate into meaningful patient benefit
- Debating the role of complement therapies in acute versus chronic disease settings and identifying how dosing strategies and endpoints may differ between the two
- Exploring the potential for complement therapeutics beyond orphan diseases, including how to position complement modulation within complex, multifactorial conditions where complement is not the primary disease driver, as well as the potential of complement in oncology
- Assessing when complement intervention should occur within the patient journey, including optimal treatment windows, sustainable dosing regimens and approaches to maximizing long-term therapeutic impact
